The objective of the study was to compare efficacy of aliskiren alone, nebivolol alone, and aliskiren and nebivolol in combination in essential hypertension patients. Methods: The study evolved 123 patients (68 males) aged 48 to 62 years with moderate-to-severe arterial hypertension. Aliskirten alone was prescribed for 41 subjects in daily doses 150-300 mg orally (1str group). Nebivolol was given for 50 Olga S. Nalotova 2 nd group patients in 5-10 mg daily orally, and combined therapy with both drug (aliskiren 150 mg daily and nebivolol 5 mg daily orally) was prescribed for 43 subjects (3 rd group). Office blood pressure, heart rate was measured at baseline and in1 weeks during 8 weeks of observation period. Blood sampling for further biochemical and biomarkers measurements was obtained at baseline and in 8 weeks. Twenty hours urine norepinephrine excretion was examined by column chromatography methods. Renin activity in plasma and concentration of aldosteron were measured by IFA method. Results: All patients have achieved a target level of blood pressure for 8 weeks of observation period. The most effective of pharmacotherapy strategy was a combination of aliskiren and nebivolol that leads reduced systolic and diastolic office blood pressure up 18.8 ± 1.2% and 18.6 ± 0.9%. However, all patients that were treated with drug combination have achieved target level of BP (less 140 / 90 mm Hg) in 2 weeks after baseline. During 8 weeks treatment period SAS and RAS activity was decreased closely in all patient groups. However, combination aliskiren and nebivolol let to overcome hyperactivation of both SAS and RAS In conclusion, combination aliskiren with nebivolol is effective in treating patients with hypertension. The significantly decreased effect on blood pressure found in patients may be attributed to decreased neurohumoral activity of the RAS and SAS
Introduction
Adequate pharmacotherapy of hypertension has always been a challenge, due to the number of hypertension variants, large number of antihypertensive drugs (AHD) [1] . Due to the important role of the sympathetic-adrenal system (SAS) and the renin-angiotensin system (RAS) in the pathogenesis of essential hypertension, active modulators of both systems for over 40 years is one of the most used drugs in primary and secondary hypertension [2, 3] . Renin-angiotensinsystem is an enzymatic cascade that plays a pivotal role in the development of arterial hypertension, kidney disease and cardiovascular disease. Inhibition of the RAS with angiotensin converting enzyme inhibitors or angiotensin receptor blockers has proved to be a successful strategy for the treatment of hypertension
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and related cardiovascular disorders. However, escape phenomenon is considered the most important cause for limitation of clinical efficacy of antihypertensive drugs that suppressed RAS [4] . The appearance of direct renin inhibitors, such as aliskiren, that are contributing to reduced secretion of angiotensin-2, were seen as a possible way to achieve more complete control of the activity of RAS and overcoming «escape phenomenon» [5, 6] . It is assumed that beta-blockers can significantly enhance the antihypertensive potenrtsial aliskiren [7] . However, So far not attempted to use the combined aliskiren and nebivolol [8] . This combination can give good results in patients with essential hypertension in the use of these drugs in minimal doses. The objective of the study was to compare efficacy of aliskiren alone, nebivolol alone, and aliskiren and nebivolol in combination in essential hypertension patients.
Methods
The study evolved 123 patients (68 males) aged 48 to 62 years with moderate-to-severe arterial hypertension. Hypertension was diagnosed according to current clinical guidelines [9] . All patients given written consent for participation in the study and they were divided into three groups depended on antihypertensive therapy. Aliskirten alone was prescribed for 41 subjects in daily doses 150-300 mg orally (1str group). Nebivolol was given for 2 nd group patients in 5-10 mg daily orally, and combined therapy with both drug (aliskiren 150 mg daily and nebivolol 5 mg daily orally) was prescribed for 43 subjects (3 rd group).
Basic characteristics for patients enrolled in the study were done in Table 1 . Office blood pressure, heart rate was measured at baseline and in1 weeks during 8 weeks of observation period. Toleration of the treatment was examined by interview provided every week for 8 weeks of the observation period.
Blood sampling for further biochemical and biomarkers measurements was obtained in the morning (at 7-8 a.m.) into cooled silicone test tubes at baseline and at the end of the study. Samples were processed according to the recommendations of the manufacturer of the analytical technique used. They were centrifuged upon permanent cooling at 6,000 rpm for 30 minutes. Then, plasma was refrigerated immediately to be stored at a temperature not higher than -20 о С.
Twenty hours urine norepinephrine excretion was examined by column chromatography methods (Jenway 6200, China). Renin activity in plasma was measured by «Immunotech angiotensin-I IFA kit» (DRG, Germany).
Concentration of aldosteron was measured by «Immunotech Аldosterone IFA kit» (DRG, Germany). Concentrations of total cholesterol and cholesterol of highdensity lipoproteins were measured by fermentation method. Concentration of cholesterol of low-density lipoproteins was calculated according to the Friedewald formula (1972). Calculation of glomerular filtration rate (GFR) was carried out using MDRD-6 formula [10] .
Statistical analysis of the results obtained was carried out in MedCalc Version 13.0.2.0. The data were presented as mean (М) and error of mean (±m). To compare the main parameters of patients' groups, ANOVA or rank KruskalWallis test were used. To compare categorical variables between groups, Chisquare test (χ 2 ) and Fisher F exact test were used. A calculated difference of P<0.05 was considered significant. Table 1 shows a general characteristic of the patients included in the study. As one can see from Table 1 , no substantial age and gender differences were found among persons. Moderate and severe arterial hypertension was defined in 58.5% and 41.5% respectively. (Table. 2). Aliskiren alone and nebivolol alone leaded (p <0,05 for all cases) to reduced systolic office blood pressure up 16.1 ± 1.3 % and 15.5 ± 1.2% respectively and diastolic office blood pressure up 15.5 ± 1.1% and 14.5 ± 1.1% respectively in 4 weeks after baseline. The most effective of pharmacotherapy strategy was a combination of aliskiren and nebivolol that leads reduced systolic and diastolic office blood pressure up 18.8 ± 1.2% and 18.6 ± 0.9%. However, all patients that were treated with drug combination have achieved target level of BP (less 140 / 90 mm Hg) in 2 weeks after baseline.
Results
Number of adverse events and withdrawals due to adverse events were similar with aliskiren (4/0), nebivolol (3/0) and combination of both drugs (3/0) (P=0.88). For all cases the adverse events were related with mild dizziness. Serious adverse events were not found. Thus, BP control is better with aliskiren combined with nebivolol. During 8 weeks treatment period SAS and RAS activity was decreased closely in all patient groups ( 
Discussion
Consequently the effect of a different pharmacological strategy that completely blocks the RAS and SAS upstream has been assessed in the last years. In this context, aliskiren is the first representative of a new class of non-peptide orally active renin inhibitor that blocks the RAS at its rate-limiting step and induces a net reduction in PRA, angiotensin-2 and aldosterone levels. This study shows that aliskiren effectively reduces blood pressure as a monotherapy as well in combination in nebivolol and that combination of both drugs lowers blood pressure superior then aliskiren alone and nebivolol alone. Therefore, combined therapy was well-tolerated. These data are related with the results obtained in recent studies [11, 12] and meta-analysis [13] . Despite results of mentioned above investigations were obtained in resistant hypertension patient population, it has expected that similar findings may be suitable for other subjects with essential hypertension [14] . However, the effect of aliskiren with nebivolol in combination on SAS and RAS activity was investigated firstly. Obviously the potential benefits of inhibiting the RAS by aliskiren alone or in combination with SAS blocker nebivolol seem to be theoretically promising and it requires new clinical investigations.
Conclusion
Combination aliskiren with nebivolol is effective in treating patients with hypertension. The significantly decreased effect on blood pressure found in patients may be attributed to decreased neurohumoral activity of the RAS and SAS.
